Nothing Special   »   [go: up one dir, main page]

Endometrial Cancer: Faina Linkov, PHD Research Assistant Professor University of Pittsburgh Cancer Institute

Download as ppt, pdf, or txt
Download as ppt, pdf, or txt
You are on page 1of 22

Endometrial Cancer

Faina Linkov, PhD


Research Assistant Professor
University of Pittsburgh Cancer Institute
GENERAL OVERVIEW OF
GYNECOLOGIC CANCERS
• 79,480 new cases/yr of female genital system
cancers in the U.S.
• 28,910 deaths in U.S. from genital system
cancers in 2005
• Diet, exercise and lifestyle choices play
important roles in the prevention of cancer
• Knowledge of family history also increases
prevention and early diagnosis rates
• Regular screening and self-examinations for
appropriate cancers  early detection early
intervention & therapy
Endometrial Cancer

• Strong association with


excess weight
Adipose tissue: Consequences of
Obesity on Cancer Development
Obesity has been implicated in the development of
• Type 2 diabetes
• Heart disease
• Stroke
• Hypertension
• Gallbladder disease
• Osteoarthritis
• Sleep apnea
• Asthma
• Psychological disorders or difficulties
• Some cancers, including ovarian,
cervical, breast, and endometrial
• Dyslipidemia
• Complications of pregnancy
• Hirsuitism
• Menstrual abnormalities
• Stress incontinence
• Increased surgical risk
Endometrial Cancer and Lifestyle
Important Definitions
• Obesity: having a very high amount of body fat in
relation to lean body mass, or Body Mass Index
(BMI) of 30 or higher for adults.
• Body Mass Index (BMI): a measure of weight in
relation to height, specifically weight in kilograms
divided by the square of his or her height in meters.
• Morbid Obesity-100 pounds above ideal weight or
BMI over 40 (indication for bariatric surgery)
• Bariatric surgery is the term for operations to help
promote weight loss.
Obesity Trends* Among U.S. Adults
BRFSS, 2005
(*BMI ≥30, or ~ 30 lbs overweight for 5’ 4” person)

No Data <10% 10%–14% 15%–19% 20%–24% 25%–29% ≥30%


ENDOMETRIAL CANCER

• Cancer of the uterine endometrial lining


• Most common female reproductive
cancer
– 40,000 new cases/year
– 7,000 deaths/year
• Most of these malignancies are
adenocarcinoma
Incidence and Prevalence
• Most common gynecologic cancer
• 4th most common in women (US)
• 2nd most common in women (UK)
• 5th most common in women (worldwide)
• Western developed > Southeast Asia
• Increase in the 1970’s
– Increased use of menopausal estrogen therapy
RISK FACTORS FOR
ENDOMETRIAL CANCER
• Early menarche • Diabetes
(<age 12) • Age greater than 40
• Late menopause • Caucasian women
(>age 52) • Family history of
• Infertility or nulliparous endometrial cancer or
hereditary nonpolyposis
• Obesity colon cancer (HNPCC)
• Treatment with tamoxifen • Personal history of breast
for breast cancer or ovarian cancer
• Estrogen replacement • Prior radiation therapy for
therapy (ERT) after pelvic cancer
menopause
• Diet high in animal fat
Endometrial Carcinoma
Etiology
• Unnoposed estrogen
hypothesis: exposure to
unopposed estrogens
Pathology
• Spreads through uterus,
fallopian tubes, ovaries
and out into peritoneal
cavity
– Metastasizes via blood and
lymphatic system
SYMPTOMS OF
ENDOMETRIAL CANCER
• Symptoms
– Non-menstrual bleeding or discharge
• Especially post-menopausal bleeding
– Heavy bleeding
– Dysuria
– Pain during intercourse
– Pain and/or mass in pelvic area
– Weight loss
– Back pain
ENDOMETRIAL CANCER

• Diagnosis • Treatment
– Pelvic examination – Surgery
– Pap smear (detect cancer • Hysterectomy
spread to cervix)
• Salpingo-oophorectomy
– Endometrial biopsy
• Pelvic lymph node
– Dilation and curettage dissection
– Transvaginal ultrasound • Laparoscopic lymph node
sampling
– Radiation therapy
– Chemotherapy
– Hormone therapy
• Progesterone
• Tamoxifen
Endometrial hyperplasia
• Overgrowth of the glandular epithelium of
the endometrial lining
• Usually occurs when a patient is exposed
to unopposed estrogen, either
estrogenically or because of anovulation
• Rates of neoplasm
– simple hyperplasia: 1%.
– complex hyperplasia with atypia: 30%
Endometrial Hyperplasia
• Complex hyperplasia with atypia
– One study found incidence of concomitant
endometrial cancer in 40% of cases
– Hysterectomy or high dose progestin tx
• Simple
– Often regress spontaneously
– Progestin treatment used for treating bleeding
may help in treating hyperplasia as well
• Estrogen dependent disease
– Prolonged exposure without the balancing effects
of progesterone
• Premalignant potential
– Endometrial hyperplasia
– Simple => 1%
– Complex => 3%
– Simple with atypia => 8%
– Complex with atypia => 29%
Reduced Risk
• Oral Contraceptives
– Combined OC => 50% reduced rate
– Actual reduction number small because
uncommon in women of child bearing age
– Long term offers protection
– Reduced risk presumably => progesterone
• Tobacco Smoking
– Some evidence that it reduces the rate
– Smokers have lower levels of estrogen and lower
rate of obesity
Prevention and Survival
• Early detection is best prevention
• Treating precancerous hyperplasia
– Hormones (progestin)
– D&C
– Hysterectomy
– 10 ~ 30% untreated develop into cancer
• Average 5 year survival
– Stage I => 72 ~ 90%
– Stage II=> 56 ~ 60%
– Stage III => 32 ~ 40%
– Stage IV => 5 ~ 11%
Potentially modifiable risk factors

Dietary factors
Isoflavones:
Phytoestrogens that
have properties
similar to selective
estrogen receptor
modulators

Soy, beans, chick peas…


Dietary fiber
Increases estrogen
excretion and
decreases estrogen
reuptake: whole
grains, vegetables,
fruits, and seaweeds
Exercise?
Summary points
• Endometrial cancer is one of the leading
gynecological cancers in the US
• Obesity is one of the key factors involved
in Endometrial cancer development
• More research is needed to explore
modifiable risk factors in endometrial
cancer development

You might also like